Medical Enquiry

A Special Approval of Medicinal Products During Public Health Emergency or Pandemic Situation has been granted in Brunei Darussalam for the product PAXLOVID™ (nirmatrelvir 150mg film-coated tablets and ritonavir 100mg film-coated tablets) for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19. The temporary authorisation permits the supply of the product based on the approval from Emergency Use Listing (EUL) of Paxlovid granted by USFDA and is subjected to the conditions stated in the approval letter.

To report a suspected adverse event or side effect related to PAXLOVID™ (nirmatrelvir/ritonavir), please contact us via the following:
Email: [email protected]

* = Mandatory Fields